Name
GS3-09 (J): Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with er+, HER2- ABC previously treated with a CDK4/6 inhibitor - Commentary by: Prof Hiroko Bando
Date & Time
Thursday, December 4, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL